Faron Pharmaceuticals has announced the appointment of Ms. Christine Roth and Dr. Marie-Louise Fjllskog as Non-Executive Directors of the company. Ms. Roth has over three decades of experience in the pharmaceutical industry and has held leadership positions at major pharmaceutical companies such as Novartis, Bristol-Myers Squibb, GlaxoSmithKline, and Bayer AG. Dr. Fjllskog has extensive experience in the pharmaceutical and biopharmaceutical industry, particularly in clinical oncology and drug development. She has held key roles in various pharmaceutical companies and is currently on the board of Biovica International AB and Lytix Biopharma.

Dr. Frank Armstrong, Chairman of the Board of Faron Pharmaceuticals, expressed his pleasure in welcoming Ms. Roth and Dr. Fjllskog to the board, stating that their combined executive experience in the oncology field and medical expertise will greatly support the advancement of bexmarilimab, Faron's investigational immunotherapy, in clinical development.

Bexmarilimab is Faron's wholly owned immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes by targeting myeloid cell function and igniting the immune system.